BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 06, 2010
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 12/03 cls
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) Brean Murray Jonathan Aschoff Price target Buy 2% $76.85
Leerink Howard Liang Price target Market outperform
Aschoff raised his target to $83 from $75 after Alexion reported final Phase II data on Nov. 20 at the American Society of Nephrology meeting that showed Soliris eculizumab met the primary endpoint in patients with atypical hemolytic uremic syndrome (aHUS). The results are consistent with the interim data announced in October (see BioCentury, Oct. 25). Soliris has Orphan Drug designation in the U.S. and EU to treat aHUS. The humanized mAb, which targets complement 5 (C5), is approved in Canada, the EU, the U.S. and Japan to treat paroxysmal nocturnal hemoglobinuria (PNH). Alexion was up 2% for the week ended Nov. 26, when Aschoff issued his report.
Liang raised his target to...

Read the full 951 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >